Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7272216 | 0.78 | HRH1 (0.60) | HRH1HTR2ASIGMAR1CHRM2SLC6A2 | |
| SCHEMBL7274896 | 0.77 | HTR2A (0.55) | HRH1HTR2ASIGMAR1MTNR1AMTNR1B | |
| SCHEMBL7272899 | 0.76 | HTR2A (0.58) | HRH1HTR2ASIGMAR1CHRM2SLC6A2 | |
| SCHEMBL10409938 | 0.76 | HTR2A (0.53) | HRH1HTR2ASIGMAR1MTNR1AMTNR1B | |
| SCHEMBL1802493 | 0.76 | HRH1 (1.00) | HRH1HTR2ASIGMAR1CHRM2SLC6A2 | |
| SCHEMBL3068671 | 0.76 | HRH1 (0.62) | HRH1HTR2ASIGMAR1CHRM2SLC6A2 | |
| SCHEMBL8297797 | 0.76 | HTR2A (0.62) | HRH1HTR2ASIGMAR1 | |
| SCHEMBL1149757 | 0.75 | HRH1 (0.56) | HRH1HTR2ASIGMAR1MTNR1AMTNR1B | |
| SCHEMBL9053055 | 0.74 | HTR2A (0.60) | HRH1HTR2ASIGMAR1MTNR1AMTNR1B | |
| SCHEMBL5154177 | 0.74 | HRH1 (0.60) | HRH1HTR2ASIGMAR1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100104649-A1 | Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate | ACTAVIS GROUP PTC EHF (IS) | 2010-04-29 | — | — | US | disclosed |
| WO-2008107797-A3 | LERCANIDIPINE HYDROCHLORIDE POLYMORPHS AND AN IMPROVED PROCESS FOR PREPARATION OF 1,1,N-TRIMETHYL-N-(3,3-DIPHENYLPROPYL)-2-AMINOETHYL ACETOACETATE | ACTAVIS GROUP PTC EHF (IS) | 2010-01-21 | — | — | WO | disclosed |
| EP-2121575-A2 | LERCANIDIPINE HYDROCHLORIDE POLYMORPHS AND AN IMPROVED PROCESS FOR PREPARATION OF 1,1,N-TRIMETHYL-N-(3,3-DIPHENYLPROPYL)-2-AMINOETHYL ACETOACETATE | Actavis Group PTC EHF (IS) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008107797-A2 | LERCANIDIPINE HYDROCHLORIDE POLYMORPHS AND AN IMPROVED PROCESS FOR PREPARATION OF 1,1,N-TRIMETHYL-N-(3,3-DIPHENYLPROPYL)-2-AMINOETHYL ACETOACETATE | ACTAVIS GROUP PTC EHF (IS) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104649-A1 | Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate | ADRB3, ADRA2C, NAT1 | HRH1 873/4885HTR2A 363/4885SIGMAR1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.